Selective Sodium Channel Modulation to Deliver Meaningful Clinical Benefits in Chronic Chemotherapy-Induced Neuropathic Pain
- A late-stage Phase 2 development program applying tetrodotoxin-based sodium channel modulation to treat chemotherapy-induced neuropathic pain
- Achieving durable pain reduction while minimizing CNS and systemic safety liabilities associated with chronic pain therapies
- Establishing clinical proof of concept for selective ion channel modulation in nonopioid pain management